Fidelity Management & Research Co recently announced the acquisition of new stake in Taysha Gene Therapies Inc (NASDAQ:TSHA). The institutional investor has increased its shareholding in the Healthcare company by 2,035.03% to 24.53 million shares with purchase of 23.38 million shares. This fresh investment now brings its stake to 13.12% valued currently at $43.17 million. In addition, RA Capital Management LP raised its holdings by 18.47 million to 18.47 million shares.
With over 4.65 million Taysha Gene Therapies Inc (TSHA) shares trading Tuesday and a closing price of $1.92 on the day, the dollar volume was approximately $8.93 million. The shares have shown a positive half year performance of 187.21% and its price on 01/09/24 gained nearly 4.35%. Currently, there are 186.96M common shares owned by the public and among those 115.80M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 18 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 11 of these insider trades were purchases, accounting for 18,231,217 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 582,095 shares.
The top 3 mutual fund holders in Taysha Gene Therapies Inc are Fidelity Select Port. – Biotechno, Vanguard Total Stock Market ETF, and Fidelity Growth Company Fund. Fidelity Select Port. – Biotechno owns 10.99 million shares of the company’s stock, all valued at over $19.35 million. Fidelity Growth Company Fund bought 0.14 million shares to bring its total holdings to over 3.67 million shares at a value of $6.46 million. Fidelity Growth Company Fund now owns shares totaling to 1.96% of the shares outstanding.
Shares of Taysha Gene Therapies Inc (NASDAQ: TSHA) opened at $1.79, down -$0.05 from a prior closing price of $1.84. The company’s stock has a 5-day price change of 12.28% and -28.36% over the past three months. TSHA shares are trading 8.47% year to date (YTD), with the 12-month market performance down to -4.48% lower. It has a 12-month low price of $0.50 and touched a high of $3.89 over the same period. TSHA has an average intraday trading volume of 2.21 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.88%, 5.26%, and 27.23% respectively.
Institutional ownership of Taysha Gene Therapies Inc (NASDAQ: TSHA) shares accounts for 55.22% of the company’s 186.96M shares outstanding. Mutual fund holders own 23.66%, while other institutional holders and individual stakeholders account for 41.47% and 13.75% respectively.
It has a market capitalization of $358.96M and a beta (3y monthly) value of -0.13. The earnings-per-share (ttm) stands at -$2.58. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.17% over the week and 8.86% over the month.
Analysts forecast that Taysha Gene Therapies Inc (TSHA) will achieve an EPS of -$0.11 for the current quarter, -$0.06 for the next quarter and -$0.44 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.24 while analysts give the company a high EPS estimate of -$0.07. Comparatively, EPS for the current quarter was -$0.99 a year ago. Earnings per share for the fiscal year are expected to increase by 61.15%, and 70.06% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 9 brokerage firm advisors rate Taysha Gene Therapies Inc (TSHA) as a “Strong Buy” at a consensus score of 1.33. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 9 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TSHA, a number of firms have released research notes about the stock. Jefferies stated their Hold rating for the stock in a research note on February 01, 2023, with the firm’s price target at $14-$1.50.
